Pharmaceutical Company
Issues generally related to the Orphan Drug Tax Credit. Consideration of issues pertaining to PKU patients lost to follow up to be included in FY 2022 Labor, Health and Human Services, Education and Related Agencies funding bills. H.R. 785, for the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, and Karla Maria Barrera De Bueso.
Policies contained in S. 2612, For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera (116th Congress). Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs; and FDA approvals of drugs designed to treat rare diseases, including gene therapies.   

Issues pertaining to newborn screening and gene panel screening, including, H.R. 2507, the Newborn Screening Saves Lives Reauthorization Act of 2019 and S. 2158, the Newborn Screening Saves Lives Reauthorization Act of 2019 (116th Congress).

Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies proposed in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements.
TAX - Taxation/Internal Revenue Code BUD - Budget/Appropriations IMM - Immigration HCR - Health Issues MMM - Medicare/Medicaid
136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce